Tailor treatment through targeted, next-generation sequencing
Traditional approaches to classify gynecologic malignancies, including immunohistochemistry and morphology, often fail to provide information on prognostic- and therapy-related associations. Molecular, or genetic, testing can reveal gene variants with clinical significance and improve outcomes for individuals affected by gynecologic cancer.
Mayo Clinic Laboratories’ MayoComplete gynecological cancer panels use next-generation sequencing to evaluate genes with known relevance to diagnosis, prognosis, and treatment of endometrial, ovarian, and sex-cord stromal tumors. An integrated team of gynecologic clinicians, geneticists, and genetic counselors carefully designed our panels to include only clinically actionable genes. Patient-centric, cost-effective, and efficient, our panels provide a detailed picture of a patient’s illness to help understand the best path forward.
Learn more about our full suite of MayoComplete next-generation sequencing panels for hematologic and oncologic conditions.
Single gene testing
Gynecological NGS panels offer cost-effective cancer testing
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' gynecological NGS panels provide focused assessments of gynecological cancers. The cost-effective tests fill the gap between single gene assays and large cancer panels, to inform prognosis and treatment.